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Trastuzumab-grafted PAMAM 
dendrimers for the selective 
delivery of anticancer drugs to 
HER2-positive breast cancer
Hitesh Kulhari1,2,3,4, Deep Pooja4, Shweta Shrivastava5, Madhusudana Kuncha4, 
V. G. M. Naidu5, Vipul Bansal1,2, Ramakrishna Sistla4 & David J. Adams1,*
Approximately 20% of breast cancer cases are human epidermal growth factor receptor 2 (HER2)-
positive. This type of breast cancer is more aggressive and tends to reoccur more often than HER2-
negative breast cancer. In this study, we synthesized trastuzumab (TZ)-grafted dendrimers to improve 
delivery of docetaxel (DTX) to HER2-positive breast cancer cells. Bioconjugation of TZ on the surface 
of dendrimers was performed using a heterocrosslinker, MAL-PEG-NHS. For imaging of cancer cells, 
dendrimers were also conjugated to fluorescein isothiocyanate. Comparative in vitro studies revealed 
that these targeted dendrimers were more selective, and had higher antiproliferation activity, towards 
HER2-positive MDA-MB-453 human breast cancer cells than HER2-negative MDA-MB-231 human 
breast cancer cells. When compared with unconjugated dendrimers, TZ-conjugated dendrimers also 
displayed higher cellular internalization and induction of apoptosis against MDA-MB-453 cells. Binding 
of TZ to the dendrimer surface could help site-specific delivery of DTX and reduce systemic toxicity 
resulting from its lack of specificity. In addition, in vivo studies revealed that the pharmacokinetic profile 
of DTX was significantly improved by the conjugated nanosystem.
In their GLOBOCAN 2012 report, the World Health Organization’s International Agency for Research on Cancer 
(IARC) states breast cancer is the second most common cancer diagnosed worldwide. In 2012, 1.7 million new 
cases were diagnosed, and more than 0.5 million women died from breast cancer. Since 2008, the incidence of 
breast cancer has increased by more than 20%, and mortality from the disease has increased by approximately 
14%1,2. Around 20% of breast cancers are HER2-positive3. That is, they express high levels of the human epider-
mal growth factor receptor type 2 (HER2) that stimulates breast cancer cell growth. HER2-positive breast cancer 
is usually more aggressive and spreads more quickly than HER2-negative breast cancer. HER2-positive breast 
cancer can also be difficult to treat with the hormone therapies used for other types of breast cancer3,4.
Adjuvant and neo-adjuvant chemotherapies play important roles in managing HER2-positive breast cancer. 
Trastuzumab (TZ) is a humanized, monoclonal antibody approved by the Food and Drug Administration USA to 
treat HER2-positive early stage and metastatic breast cancer. It binds with HER2 receptors on breast cancer cells 
and blocks downstream signalling, leading to antibody-dependent cellular toxicity4–7.
In breast cancer, TZ can be used as a single agent and in combination with standard chemotherapy8. 
Combining TZ with other chemotherapeutic agents, such as taxanes and anthracyclines, has been seen to sig-
nificantly improve disease-free survival rates and overall survival rates. When combined with docetaxel (DTX), 
TZ also shows synergistic effects9. The patients given a TZ-DTX combination treatment had a greater chance 
(p = 0.03) of survival (31.2 months) than people given DTX alone (22.7 months) but also suffered a higher 
incidence of febrile neutropenia and symptomatic heart failure10.
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Step No. Conjugate Zeta Potential (mV)
1 Dendrimers 12.3 ± 0.9
2 Dendrimer PEG-NHS ester 6.8 ± 1.5
3 Dend-TZ conjugate − 2.3 ± 0.6
Table 1.  Zeta potential value of plain dendrimers, dendrimer-PEG-NHS ester and dendrimer-
Trastuzumab conjugate (Dend-TZ).
Figure 1. Schematic diagram illustrating the synthesis of Trastuzumab (TZ)-grafted, fluorescein isothiocyanate 
(FITC)-labelled G4 poly(amido) amine (PAMAM) dendrimers. In step 1, FITC was conjugated to G4 PAMAM 
dendrimers. In step 2, FITC-labelled dendrimers were crosslinked with MAL-PEG-NHS to give Dend-PEG-
MAL (Product A). In step 3, TZ was thiolated using Traut’s reagent (2-iminothiolane) to give thiolated TZ. 
Finally, in step 4, Dend-PEG-MAL (Product A) was reacted to thiolated TZ (Product B) to synthesize TZ-
grafted FITC-labelled G4 PAMAM dendrimers.
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The specific binding of TZ to HER2 receptors has been explored to develop targeted systems for the imaging 
and delivery of anticancer drugs to HER2-positive breast cancer cells11,12. The presence of free functional groups 
(-NH2 and -COOH) on the surface of TZ provides the opppurtinity for conjugation of TZ to various drug car-
riers. TZ has been conjugated to different nanocarriers such as G4 poly(amido)amine (PAMAM) dendrimers, 
poly(lectic-co-glycolic acid), chitosan and albumin for targeted delivery of anticancer drugs and genes12–16.
Figure 2. In vitro release of docetaxel (DTX) from three different formulations: Taxotere, DTX-loaded 
PAMAM dendrimers (Dend-DTX), and trastuzumab-conjugated Dend-DTX (TZ-Dend-DTX) in 
phosphate buffer saline (PBS) pH 7.4 (Mean ± SD; n = 3). 
Figure 3. % Hemolysis caused by plain G4 PAMAM amine dendrimers (plain Dend) and trastuzumab-
conjugated dendrimers (TZ-Dend) at various concentration levels (Mean ± SD; n = 3). 
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DTX is a semi-synthetic paclitaxel analogue, and has been used as a first-line treatment for various cancers, 
including breast, lung, ovarian, brain and prostate cancers. Despite wide spectrum activity, its clinical applica-
tion is restricted due its poor aqueous solibility, low bioavailability, non-specific toxicity and intolerable side 
effects17–21. Dendrimers have an ideal structure to develop a targeted drug delivery system where drug molecules 
can be encapsulated in the internal cavities while conjugating a targeting ligand to the free functional groups on 
the surface. Dendrimers are hyper-branched, nano-sized and multifunctional carrier systems having open inter-
nal cavities and free functional groups on their surface22–27.
Although reports detail conjugation of TZ to a nanocarrier system28–32, preclinical studies comparing the  pharma-
cokinetic profile of conjugated system versus non-conjugated system and plain drug have not been reported. To this 
end, we have loaded DTX into amine terminated PAMAM dendrimers through non-covalent interactions and conju-
gated TZ to the dendrimers using a cross-linker MAL-PEG-NHS. This TZ grafted dendrimer-mediated drug delivery 
system was evaluated for controlled release of drug and site specific delivery of DTX to HER2 positive cancer cells. This 
study also aimed to elucidate the pharmacokinetic profile of the conjugated system.
Results and Discussion
Synthesis and characterization of trastuzumab-grafted PAMAM dendrimers. TZ was conju-
gated onto the surface of dendrimers by a four-step chemical reaction (Figure 1). Fluorescein isothiocyanate 
(FITC)-labelled dendrimers were synthesized by reacting the primary amino groups of the dendrimers with the 
FITC isothiocyanate groups. This reaction created a stable thiourea bond. UV/Vis spectrophotometric analysis 
revealed that approximately 4.6 FITC molecules were attached per dendrimer molecule (Fig. S1a). FITC-labelled 
dendrimers were crosslinked with the N-hydroxysuccinimide (NHS) ester of PEG-MAL. 1H NMR analysis con-
firmed pegylated dendrimer synthesis. Two new peaks appeared at 3.65 and 6.82 ppm, corresponding with PEG 
chain and MAL methylene group protons, respectively. This confirmed substantial conjugation between den-
drimers and NHS-PEG-MAL (Fig. S1b).
In a separate reaction, TZ was thiolated using Traut’s reagent (2-iminothiolane hydrochloride) and the num-
ber of thiol groups on the TZ was determined using Ellmann’s test. Approximately 3.2 thiol groups were generated 
on per molecule of TZ. Thiolated TZ was then reacted with pegylated dendrimers, and conjugation confirmed by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis (Fig. S1c).
Conjugation was also confirmed at various stages by studying the changes in surface charge of the dendrim-
ers (Table 1). Due to the cationic 64-amine groups on their surface, plain dendrimers showed a positive zeta 
potential of 12.7 mV. After conjugation with NHS-PEG-MAL, the zeta potential decreased to 6.8 mV and, after 
TZ was grafted onto the dendrimer surface, it further reduced to − 2.3 mV. Since TZ has an isoelectric point (pI) 
of 8.5, with an overall anionic nature at physiological pH, the reduction in zeta potential value supports success-
ful conjugation of TZ with the dendrimers. The hydrodynamic diameter of PAMAM dendrimer, TZ-Dend and 
TZ-Dend-DTX was 12.8 ± 1.3 nm, 29.1 ± 3.9 nm and 31.6 ± 2.1 nm, respectively.
DTX loading and in vitro drug release. DTX was loaded into plain dendrimers to a concentra-
tion of 241.7 ± 3.8 μg/mL. In TZ-Dend conjugates, the DTX loading concentration decreased significantly to 
159.5 ± 5.4 μg/mL. This decrease may be due to presence of TZ on the dendrimer surface, which may restrict the 
DTX molecules’ access to the interior cavities. When dendrimers were conjugated with TZ after DTX loading, 
DTX concentration was 216.4 ± 2.79 μg/mL. In this case, the decrease in DTX loading (compared with plain 
dendrimers) may be due to loss or release of drug during the conjugation process. Since drug loading was higher 
when DTX loading occurred before TZ conjugation, we used this system in our further studies.
Figure 4. Percentage cell viability of (a) MDA-MB-453 and (b) MDA-MB-231 human breast cancer cells 
treated with varying concentrations of docetaxel (DTX), DTX-loaded PAMAM dendrimers (Dend-DTX) and 
trastuzumab-conjugated Dend-DTX (TZ-Dend-DTX) (Mean ± SD; n = 3). TZ-conjugated empty dendrimers 
were used as control.
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DTX release from Taxotere (a commercial DTX formulation), Dend-DTX and TZ-Dend-DTX was monitored 
in phosphate buffer saline (PBS) (Fig. 2). DTX was released faster from Taxotere than from dendrimer-mediated 
formulations. About 94% of DTX was released from Taxotere within 10 h. In contrast, Dend-DTX and 
TZ-Dend-DTX displayed controlled release of the drug over 48 h. Dend-DTX released 71.84% of drug after 24 h 
and 93.5% of drug after 48 h. TZ-Dend-DTX had better drug release properties than Dend-DTX or Taxotere 
alone, with DTX release at 58.6% after 24 h and 73.9% after 48 h. This slower release is likely due to the presence 
of TZ on the dendrimer surface, which could make a long release path for the drug or create a coat around the 
dendrimers that decreases the diffusion of drug from dendrimers.
Hemolytic toxicity. Biocompatibility of the drug delivery carrier was assessed by studying hemolytic tox-
icity. Plain dendrimers showed concentration-dependent hemolysis (Fig. 3). TZ-conjugated dendrimers caused 
lower hemolysis than plain dendrimers. At 10 mg/mL dendrimer concentration, plain dendrimers caused 
5.3% hemolysis, compared with TZ-Dend conjugates which caused 1.5% hemolysis. These results suggest that 
TZ-Dend conjugates are more biocompatible than plain dendrimers with reduced hemolysis. The lower tox-
icity of TZ-Dend conjugates than plain dendrimers can be explained by the opposite charges on their surfaces 
(Table 1). Plain dendrimers have a high positive charge of 12.7 mV, whereas TZ-Dend conjugates were mildly 
anionic in nature, with a zeta potential value of − 2.3 mV. PAMAM dendrimers cause hemolysis because of their 
cationic nature. They rapidly interact with the anionic membrane of red blood cells (RBC), causing hemolysis33. 
The TZ moiety on TZ-Dend conjugates neutralized this positive charge, making these conjugates slightly anionic, 
and decreasing the interaction between dendrimers and RBC membranes.
In vitro cytotoxicity. Two breast cancer lines (MDA-MB-453 and MDA-MB-231) were used to investi-
gate the anticancer actions of DTX formulations. These cell lines were chosen for their immuno-profiles. 
MDA-MB-453 cells are estrogen receptor-negative (ER−), progesterone receptor-negative (PR−) and 
HER2-positive. MDA-MB-231 cells are triple-negative (ER−, PR− and HER2-negative). Moreover, both cell lines 
have a similar sensitivity to chemotherapy34,35. Therefore, a comparative evaluation of cytotoxicity against these 
cell lines could provide a good understanding of the contribution of TZ in targeting HER2-positive breast cancers.
Cytotoxicity measures of DTX, Dend-DTX and TZ-Dend-DTX against MDA-MB-453 and MDA-MB-231 
cells are shown in Fig. 4a and Fig. 4b, respectively. At 125 ng/mL drug concentration, MDA-MB-453 cell via-
bility after 48 h of treatment was 69.0, 57.6 and 36.2% for DTX, Dend-DTX and TZ-Dend-DTX, respectively. 
The results clearly indicated that DTX-loaded dendrimers were significantly more cytotoxic (p < 0.0005) than 
plain DTX. Comparing targeted and non-targeted dendrimers, TZ-Dend-DTX was more cytotoxic (p < 0.0005) 
than Dend-DTX in MDA-MB-453 cells. This may be due to the interaction between TZ and HER2 receptors 
in these cells, which makes internalization of TZ-Dend-DTX through receptor-mediated endocytosis more 
Figure 5. Morphology of MDA-MB-453 human breast cancer cells treated with 56 ng/mL of docetaxel 
(DTX), DTX-loaded PAMAM dendrimers (Dend-DTX) and trastuzumab-conjugated Dend-DTX  
(TZ-Dend-DTX). 
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efficient. However, TZ-Dend-DTX did not cause significantly (p > 0.05) higher cytotoxicity than Dend-DTX 
in MDA-MB-231 cells. MDA-MB-231 cell viability after 48 h of treatment was 61.9, 59.3 and 60.9% for DTX, 
Dend-DTX and TZ-Dend-DTX, respectively (Fig. 4b).
All of the formulations also caused dose-dependent cytotoxicity in both cell lines. Cell viability decreased 
with increased drug concentrations. Against HER2-positive MDA-MB-453 cells, the half-maximal inhibitory 
concentration (IC50) values for Dend-DTX and TZ-Dend-DTX were 201 ng/mL and 56.18 ng/mL, respectively 
(Table S1). Therefore, the TZ-Dend-DTX conjugate was 3.57 times more cytotoxic than Dend-DTX. However, 
against HER2-negative MDA-MB-231 cells, the TZ-Dend-DTX conjugate was not significantly more effective 
than that of Dend-DTX. The IC50 value for Dend-DTX and TZ-Dend-DTX against MDA-MB-231 cells was 
163.4 ng/mL and 149.5 ng/mL, respectively. Even at very low concentration (7.8 ng/mL), the TZ-Dend-DTX 
Figure 6. (a) Fluorescent microscopic images of MDA-MB-453 and MDA-MB-231 human breast cancer cells 
after 1 h and 4 h of incubation with FITC-conjugated dendrimers (Dend-FITC) and TZ-conjugated Dend-FITC 
(TZ-Dend-FITC); (b) Fluorescent microscopic images of cocultured MDA-MB-453 and MDA-MB-231 human 
breast cancer cells followed by incubation with TZ-Dend-FITC; (c) Quantitative uptake of TZ-Dend-FITC by 
MDA-MB-453 and MDA-MB-231 human breast cancer cells after 2 h incubation with or without TZ (20 mM).
Formulation
MDA-MB-453 MDA-MB-231
% Cell uptake 
after 1 h
% Cell uptake 
after 4 h
% Cell uptake 
after 1 h
% Cell uptake 
after 4 h
Dend-FITC 11.28 ± 1.4 34.2 ± 1.95 5.39 ± 2.6 12.57 ± 3.1
TZ-Dend-FITC 23.49 ± 1.85*** 57.92 ± 2.71*** 8.65 ± 1.9ns 17.06 ± 2.4ns
Table 2.  Cellular uptake of Dend-FITC and TZ-Dend-FITC by human breast cancer cells MDA-MB-453 
and MDA-MB-231 after 1 and 4 h of incubation. *Indicates comparison with Dend-DTX (ns Not Significant, 
***p < 0.0005).
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showed significantly (p < 0.05) higher cytotoxicity against HER2 positive MDA-MB-453 cells than Dend-DTX, 
but no significant difference (p > 0.05) in cytotoxicity against HER2 negative MDA-MB-231 cells. These results 
demonstrate that TZ can specifically target and deliver DTX to HER2-positive cells. After treatment with different 
DTX formulations, changes in cell morphology and a decrease in the number of viable MDA-MB-453 cells were 
observed (Fig. 5). TZ-conjugated empty dendrimers were used as a control and did not show significant toxicity.
Cellular uptake. Cellular uptake studies are important tools to track the internalization of fluorescent nan-
oparticles. Dend-FITC and TZ-Dend-FITC uptake was observed in both MDA-MB-453 (HER2-positive) and 
MDA-MB-231(HER2-negative) cells, and the results are shown in Fig. 6. In the case of MDA-MB-453, both 
Dend-FITC and TZ-Dend-FITC showed fluorescence after just 1 h. Fluorescence intensity was significantly 
higher after treatment with TZ-Dend-FITC than with Dend-FITC. These results were confirmed by quantitative 
analysis (Table 2). After 1 h of treatment, Dend-FITC and TZ-Dend-FITC uptake was 11.4% and 23.5%, respec-
tively. Dendrimer formulations also showed time-dependent uptake. After 4 h of incubation, uptake increased to 
34.2% and 57.9% for Dend-FITC and TZ-Dend-FITC, respectively. The significantly (p < 0.0005) higher uptake 
of TZ-Dend-FITC than Dend-FITC clearly demonstrates significance of TZ in the internalization of dendrimers 
in HER2-positive cells.
In contrast, both dendrimer formulations did not show any significant differences (p > 0.05) in cellular uptake 
in MDA-MB-231 which was also evident from quantitative data (Table 2). In order to confirm the selective tar-
geting of TZ-Dend-FITC to HER2 positive cells, cellular uptake of TZ-Dend-FITC was observed in co-cultured 
(MDA-MB-453 and MDA-MB-231) cells. As shown in Fig. 6b, TZ-Dend-FITC was selectively uptaken by 
MDA-MB-453 cells (round in morphology). The competition assay demonstrated that the cellular uptake of 
TZ-Dend-FITC was significantly (p < 0.05) inhibited in the presence of TZ in MDA-MB-453 cells (Fig. 6c). 
These results revealed that the TZ conjugated dendrimers are uptaken more efficiently by HER2 overexpressing 
MDA-MB-453 cells.
Qualitative determination of apoptosis with acridine orange and ethidium bromide stain-
ing. Acridine orange (AO) stains live and dead cells, whereas ethidium bromide (EB) stains only dead cells or 
cells that have lost membrane integrity. Therefore, staining is interpreted as follows:
•	 live cells: uniformly green with intact nuclei
•	 early apoptotic cells: green with intense green dots at the center due to chromatin condensation and nuclear 
fragmentation
•	 late apoptotic cells: orange with chromatin condensation and fragmented nuclei.
Figure 7. Qualitative determination of apoptosis induced by various DTX formulations, created with an 
AO/EB double-staining assay. Figure shows the fluorescent microscopic images of MDA-MB-453 human 
breast cancer cells after treatment with 56 ng/mL of docetaxel (DTX), DTX-loaded PAMAM dendrimers 
(Dend-DTX) and trastuzumab-conjugated Dend-DTX (TZ-Dend-DTX) for 24 h, then stained with 5 ng/mL 
each of AO and EB. Green, yellow and red arrows represent live cells, early apoptotic cells and late apoptotic 
cells, respectively.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:23179 | DOI: 10.1038/srep23179
Figure 7 shows the fluorescent images of untreated MDA-MB-453 cells, and cells treated with DTX, 
Dend-DTX and TZ-Dend-DTX after AO/EB double-staining. Untreated cells were an evenly spread green. 
Comparing the targeted and non-targeted dendrimers, cells treated with TZ-Dend-DTX showed greater apopto-
sis than those treated with Dend-DTX.
Quantitative determination of apoptosis with an Annexin-V FITC/PI assay. Quantitation of 
apoptosis induced by different DTX formulations was studied with an Annexin-V FITC/PI assay (Fig. 8). A 
high-percentage of live cells (94.9%) was observed in untreated cells. The percentage of live cells decreased to 
83.1% after DTX treatment, 64.6% after Dend-DTX treatment and 54.4% after TZ-Dend-DTX treatment. These 
data suggest that TZ-Dend-DTX induced more apoptosis than TZ-unconjugated and free DTX. The total per-
centage of apoptotic cells was 42.6%, 32.7% and 16.5% for TZ-Dend-DTX, Dend-DTX and DTX, respectively. 
Higher levels of apoptosis in TZ-conjugated dendrimers than unconjugated dendrimer-treated cells is likely due 
to an increased uptake and higher accumulation of DTX in these cells, which inhibits cellular proliferation.
Pharmacokinetic studies. Plasma-concentration profiles of DTX after intravenous injection of Taxotere, 
TZ-Dend-DTX and Dend-DTX are shown in Fig. 9 and correspond with the pharmacokinetic parameters 
in Table 3. Results suggest that the plasma pharmacokinetics of dendrimer conjugates (TZ-Dend-DTX and 
Dend-DTX) differed remarkably from that of Taxotere. The area-under-the-curve (AUC0−∞) of TZ-Dend-DTX 
(271.6 μg.h/mL) and Dend-DTX (204.2 μg.h/mL) was approximately 4.7 and 3.5 times higher, respectively, 
than that of Taxotere (57.2 μg.h/mL). This could be explained by the low amount of DTX released from 
dendrimer-based formulations. The observed clearance values for Taxotere, Dend-DTX and TZ-Dend-DTX were 
268.8, 48.9 (5.5 times less) and 36.8 mL/h (7.3 times less), respectively. Mean residence time (MRT) increased by 
approximately 3.4 times and 2.5 times for TZ-Dend-DTX and Dend-DTX, respectively.
Compared with TZ-unconjugated dendrimers (Dend-DTX), TZ-Dend-DTX induced a significantly higher 
AUC0−∞ (271.6 versus 204.2, p < 0.005), lower clearance (36.8 versus 48.9, p < 0.05), and longer MRT values 
Figure 8. Quantitative determination of apoptosis induced by various DTX formulations, created with an 
annexin V FITC/PI assay. MDA-MB-453 human breast cancer cells were treated with 56 ng/mL of docetaxel 
(DTX), DTX-loaded PAMAM dendrimers (Dend-DTX) and trastuzumab-conjugated Dend-DTX (TZ-Dend-
DTX) for 24 h.
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(6.85 versus 4.99; p < 0.05). The differences between the two dendrimer formulations may be attributed to the 
presence of PEG-linkers and TZ on the surface of TZ-Dend-DTX. PEG is a well-documented molecule that could 
alter the pharmacokinetics of different nanocarrier systems36–39. Being an antifouling molecule, PEG increases the 
circulation time of nanoparticles in the blood stream by delaying their capture by the reticulo-endothelial system. 
Additionally, TZ is a high molecular weight, clinically approved mAb (~145 KD), known for its high specificity for 
HER2 receptors40. It may therefore lengthen TZ-Dend-DTX circulation and slow release of DTX from conjugated 
dendrimers.
Figure 9. Time profiles of docetaxel (DTX) concentration in the plasma after intravenous administration 
of Taxotere, DTX-loaded G4 PAMAM amine dendrimers (Dend-DTX) and trastuzumab-conjugated Dend-
DTX (TZ-Dend-DTX). Formulations were administered to BAlb/c mice at a dose of 10 mg/Kg, based on DTX. 
Data is expressed as Mean ± SD (n = 4).
PK Parameter Taxotere Dend-DTX TZ-Dend-DTX
Cmax (μg/mL) 42.7 ± 1.82 69.01 ± 4.38** 61.72 ± 3.92**
,ns
T1/2 (h) 1.35 ± 0.21 1.99 ± 0.3* 3.24 ± 0.17*
,#
Cl (mL/h) 268.81 ± 11.2 48.97 ± 5.65** 36.82 ± 4.06**,#
AUC0−∞ 37.2 ± 2.94 204.16 ± 8.03*** 271.58 ± 7.95***
,##
MRT (h) 1.98 ± 0.08 4.99 ± 0.19** 6.85 ± 0.11***,##
Table 3.  Pharmacokinetic parameters for the three DTX formulations-Taxotere, DTX loaded dendrimers 
(Dend-DTX) and Trastuzumab grafted Dend-DTX (TZ-Dend-DTX). *Indicates comparison with Taxotere; 
# Indicates comparison with Dend-DTX. Statistical analysis: ns Not Significant, *p < 0.05, **p < 0.005, 
***p < 0.0005, #p < 0.05, ##p < 0.005.
Parameter Day 0 Day 60
Precipitation No No
Change in consistency No + 
ZP (mV) − 2.3 ± 0.72 − 3.89 ± 0.51
% DTX content 100 99.12
Table 4.  Physicochemical stability of TZ-Dend-DTX conjugate after 60 days of storage in refrigeration 
conditions (4 °C).
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Stability studies. After two months of storage of TZ-Dend-DTX in the refrigerator at 4 °C, there was a slight 
change in consistency, however no signs of precipitation or significant change in zeta potential and drug content 
was observed. (Table 4).
In summary, multifunctional TZ-conjugated dendrimers were synthesized using a heterocross-linker 
MAL-PEG-NHS and characterized by DLS, NMR and PAGE analysis. Targeted dendrimers selectively and 
specifically targeted DTX to HER2-positive breast cancer cells. Targeted TZ-Dend-DTX inhibited the growth 
of HER2-positive cancer cells to a greater extent than non-targeted Dend-DTX, as demonstrated by our 
anti-proliferation and apoptosis studies. Furthermore, grafting TZ onto the surface of dendrimers decreased the 
hemolytic toxicity of unconjugated cationic PAMAM dendrimers and enhanced the circulation half-life of the 
conjugate. These findings could help to develop a better therapeutic profile for DTX and deliver better health 
outcomes for people with HER2-positive cancer.
Methods
Materials. G4 PAMAM dendrimers (MW: 14215 Da) with a diaminobutane core were purchased from 
NanoSynthons (Mt Pleasant, MI). TZ was purchased from Nava Sanjivani Drugs (Hyderabad, India). MAL-PEG-
NHS (MW: 865.92 Da) was purchased from Thermo Fisher Scientific. DTX was a gift from TherDose Pharma Pvt 
Ltd (Hyderabad, India). High-performance liquid chromatography (HPLC) grade solvents were purchased from 
Merck specialties (Mumbai, India). Nylon membrane filters with a pore size of 0.22 μm were obtained from Pall 
India Pvt Ltd (Mumbai, India). FITC, dialysis tubing (molecular weight cut off 2000), Dulbecco’s modified eagle 
medium (DMEM), trypsin–EDTA, antibiotic/anti-mycotic solution, PBS (Ca2+, Mg2+ free), 3-(4, 5- dimethylth-
iazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), annexin V-FITC apoptosis 
detection kit, AO and EB were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum was 
purchased from Gibco, USA. Cell culture plastic ware was purchased from Tarson Ltd (Mumbai, India).
Synthesis and characterization of FITC-labelled, TZ-conjugated PAMAM dendrimers. FITC- 
labelled, TZ-conjugated PAMAM dendrimers were synthesized in a four-step chemical reaction:
1. synthesis of FITC-labelled dendrimers
2. conjugation of heterocross-linker to FITC-labelled dendrimers
3. TZ thiolation
4. bioconjugation of thiolated TZ with dendrimers.
Synthesis of FITC-labelled dendrimers. FITC-labelled G4 PAMAM dendrimers were prepared using a pre-
viously reported method with slight modifications41. Dendrimers were dissolved in PBS (pH 7.4) and mixed 
with FITC solution in 1:6 molar ratio. The mixture was stirred overnight, then dialyzed against PBS for 24 h to 
remove unconjugated or free FITC. The molar ratio of FITC conjugation to dendrimers was determined from 
absorbance at 495 nm using a UV-VIS spectrophotometer. For qualitative analysis, samples were scanned in the 
wavelength-range of 200–800 nm. The FITC-labelled dendrimer solution was lyophilized and used for further 
reactions.
Conjugation of heterocross-linker, Maleimide-poly(ethylene) glycol-N-hydroxysuccinimide (NHS-PEG-MAL) to 
FITC-labelled dendrimers. NHS ester of PEG-MAL was reacted with FITC-conjugated dendrimer in a molar 
ratio of 3:1 in PBS (pH 8) and stirred for 30 minutes at room temperature. Dend-PEG-MAL synthesis was char-
acterized by 1H NMR spectroscopy. Dend-PEG-MAL conjugate was dissolved in D2O and scanned using Avance 
500 NMR.
TZ thiolation. We dissolved TZ in PBS, and reacted with 2-iminothiolane hydrochloride in 1:10 molar ratio 
for 2 h. Thiolated TZ was purified by dialysis (MW cut-off 12000–14000) in PBS to remove the 2-iminothiolane 
hydrochloride.
Bioconjugation of thiolated TZ with dendrimers (TZ-Dend). Thiolated TZ was coupled with heterocross-linked, 
conjugated, FITC-labelled dendrimers (10:1 ratio) to give a bioconjugate. The NHS-PEG-MAL cross-linked den-
drimer solution was mixed with the thiolated TZ solution and allowed to react at room temperature overnight. 
TZ-Dend conjugate was purified using size exclusion chromatography (Sephadex column G-25 M) and eluted 
with PBS, pH 7.4.
Characterization of TZ-Dend conjugate. The surface potential of various nanoconjugates was measured 
using a Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd, UK). Samples were diluted in deionized water and 
analyzed at 25 °C. TZ-Dend conjugates were also characterized by PAGE analysis. All gels were electrophoresed 
under reducing conditions using Mini-Protean II electrophoresis units from BioRad at a constant voltage of 200 V 
in Tris/glycine/SDS buffer. The hydrodynamic diameter of PAMAM dendrimers, TZ-Dend and TZ-Dend-DTX 
was determined using a Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd., Malvern, Worcestershire, UK).
Drug loading. An excess (5 mg) of DTX was added to the dendrimer solution, sonicated for 30 sec, and 
gently stirred overnight. Two approaches were used to prepare TZ-Dend-DTX formulations. In first method, 
DTX-loaded dendrimers were conjugated with TZ. In the second method, DTX was loaded into Dend-TZ 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:23179 | DOI: 10.1038/srep23179
conjugates. Formulations were equilibrated for 24 h, then filtered through a 0.45 μm nylon membrane filter. The 
concentration of DTX was determined by HPLC, as per our previously validated method18.
In vitro drug release studies. In vitro drug release was studied using a dialysis method in PBS (pH 7.4). 
Taxotere and dendrimer formulations, equivalent to 2 mg of DTX, were placed in dialysis tubing (MWCO 2000) 
in release medium (100 mL of PBS) at 37 °C and stirred at 100 rpm. At different time intervals, an aliquot of 1 mL 
was withdrawn from the release medium and replaced with the same volume of fresh medium. The samples were 
appropriately diluted, filtered through a 0.22 μm nylon filter, and analyzed with HPLC for DTX content.
Cell culture. Human breast cancer cell lines MDA-MB-453 (HER2-positive) and MDA-MB-231 
(HER2-negative) were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells 
were grown in DMEM medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL 
streptomycin and 2 mM/L L-glutamine. Cells were maintained at 37 °C in 5% CO2.
Anti-proliferation assay. Cells were seeded in 96-well plates at a density of 5 × 103 cells per well in 
100 μL of medium. They were allowed to adhere overnight before being incubated with DTX, or Dend-DTX or 
TZ-Dend-DTX, at equivalent drug concentrations ranging from 5–250 ng/mL for 48 h. Media were then replaced 
with serum-free DMEM containing MTT (0.5 mg/mL), then cells were incubated for 4 h. Media were removed 
and 150 μL of DMSO was added to dissolve formazan crystals. Absorbance was measured at 570 nm using a 
microplate reader. Untreated cells were used as a negative control (100% viability). IC50 was calculated by fitting 
the curve of cell viability against the drug concentration.
Cellular uptake studies. For qualitative uptake studies, cells were seeded in 12-well plates. After 24 h, cells 
were incubated with Dend-FITC or TZ-Dend-FITC conjugates, at an equivalent FITC concentration (100 μg/mL). 
For competitive binding studies, cells were preincubated with an excess (20 mM) of TZ for 2 h and then treated 
with TZ-Dend-FITC. Culture media was removed at pre-determined time intervals. Cells were then rinsed twice 
with cold PBS and observed by fluorescence microscopy. For selective cellular uptake studies, both MDA-MB-453 
and MDA-MB-231 cells were cocultured and treated with TZ-Dend-FITC conjugate. For quantitative studies, 
0.1% Triton X-100 in 0.2 M NaOH was added to each well to lyse cells. Fluorescence intensities were measured 
using a microplate reader at an excitation wavelength of 495 nm and emission wavelength of 520 nm.
AO/EB double-staining assay. AO/EB assays were used to visualize changes in cell morphology, such as 
chromatin condensation and apoptotic body formation, which are characteristic of apoptosis. MDA-MB-453 
cells were seeded in six-well plates at 5 × 105 cells per well, in 2 mL of DMEM, and cultured for 24 h. Cells were 
incubated with various DTX formulations (DTX, Dend-DTX or TZ-Dend-DTX), equivalent to 56 ng/mL 
of DTX. After 24 h, the medium was removed and cells were washed twice in PBS before being incubated in 
PBS-containing AO and EB (5 μg/mL of each) at 37 °C for 10 min. Cell viability was observed with a fluorescence 
microscope.
Apoptosis. To evaluate apoptosis and necrosis, we used Annexin V-FITC/PI assays, as per the manufacturer’s 
protocols. Briefly, MDA-MB-453 cells (1 × 106 cells/well) were seeded in six-well plates and maintained at 37 °C in 
5% CO2 and a 95% humidified atmosphere. The medium was replaced with freshly prepared medium containing 
drug-loaded formulations. Untreated cells were used as controls. After 24 h, cells were washed twice with PBS 
and resuspended in 500 μL of binding buffer. We added 5 μL of FITC-conjugated Annexin V and 10 μL of PI, and 
incubated cells for 15 min at room temperature in the dark. Cells were then analyzed by a Muse™ Cell Analyzer 
(Merck-Millipore, Germany) and the extent of apoptosis and necrosis was determined.
Pharmacokinetic studies. Female Balb/c mice were purchased from the National Institute of Nutrition 
(Hyderabad, India). The Institutional Animal Ethics Committee (IAEC) of the CSIR-Indian Institute of Chemical 
Technology, Hyderabad, approved all experimental protocols for the study. All animal studies were performed in 
accordance with the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA). Animals were kept in polypropylene cages under standard laboratory conditions (12 h light, 
12 h dark cycle).
Eighty-four female mice (20–25 g) were randomly assigned to three groups for pharmacokinetic investiga-
tions. Taxotere, Dend-DTX or TZ-Dend-DTX was injected via the tail vein at an equivalent dose of 10 mg/kg 
DTX. At scheduled time intervals (0.25, 0.5, 1, 2, 4, 8 and 12 h) post-injection, 0.3 mL of blood was collected into 
heparinized polyethylene tubes from the retro-orbital plexus and centrifuged at 1500 rpm for 5 min to obtain 
plasma. The samples were stored at − 80 °C until they were analyzed.
The analytical method for determining the DTX content of plasma samples was validated using an HPLC 
system (Water, USA) equipped with a C18 column (Grace, 250 × 4.6 mm, 5 μm) and a photodiode array detec-
tor42. The mobile phase consisted of acetonitrile (48%) and 0.1% orthophosphoric acid (52%). 5 μL of paclitaxel 
solution (1 mg/mL) was used as an internal standard. The flow rate was maintained at 1 mL/min, and the column 
temperature was set at 25 ± 5 °C. Peaks were monitored at a wavelength of 230 nm. Retention times for DTX and 
PTX were 9.1 min and 11.2 min, respectively.
Stability studies. The final formulation (TZ-Dend-DTX) was stored at 4 °C for 60 days. The formulation 
was monitored for any changes in consistency and precipitation, and analyzed for zeta potential and drug content.
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Statistical analysis. Results are expressed as the mean and standard deviation of three experiments (n = 3). 
Pharmacokinetic data are an average of four experiments (n = 4) and pharmacokinetic parameters were calcu-
lated using WinNonlin® software (Certara USA Inc., Princeton, NJ). Statistical significance was analyzed using 
the student t-test for two groups and one-way ANOVA for multiple groups. A probability (p) of less than 0.05 was 
considered as statistically significant.
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